金陵药业：关于分公司收到药物临床试验批准通知书的公告

Core Viewpoint - Jinling Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of Olarogiv, marking a significant step in the development of this drug [2]. Group 1 - Jinling Pharmaceutical announced on September 3 that its subsidiary, Nanjing Jinling Pharmaceutical Factory, received a clinical trial application acceptance notice for Olarogiv on June 24, 2025 [2]. - The company has now obtained the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, allowing it to conduct Phase III clinical research for Olarogiv [2].